共 50 条
- [41] PHASE II TRIAL OF NON-MYELOABLATIVE CONDITIONING AND PARTIALLY HLA-MISMATCHED (HLA-HAPLOIDENTICAL) BONE MARROW TRANSPLANTATION (BMT) FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES: RESULTS OF BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS NETWORK (BMT CTN) PROTOCOL 0603 [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S151 - S151
- [44] High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia [J]. Annals of Hematology, 2009, 88 : 1015 - 1024
- [46] The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis [J]. Bone Marrow Transplantation, 2010, 45 : 985 - 992
- [48] Reconstitution of natural killer cell receptor repertoires after unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation:: Analyses of CD94: NKG2A and killer immunoglobulin-like receptor expression and their associations with clinical outcome [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (06) : 734 - 744
- [50] Modified Donor Lymphocyte Infusion after HLA-Mismatched/Haploidentical T Cell-replete Hematopoietic Stem Cell Transplantation for Prophylaxis of Relapse of Leukemia in Patients with Advanced Leukemia [J]. Journal of Clinical Immunology, 2008, 28 : 276 - 283